Scott C Olson1, Sherilyn Smith2, Scott J Weissman3, Matthew P Kronman2. 1. Department of Pediatrics Division of Infectious Diseases, University of Washington, Seattle. 2. Department of Pediatrics Division of Infectious Diseases, University of Washington, Seattle Center for Clinical and Translational Research. 3. Department of Pediatrics Division of Infectious Diseases, University of Washington, Seattle Center for Global Infectious Disease Research, Seattle Children's Hospital Research Institute, Washington.
Abstract
BACKGROUND: Although long treatment courses of outpatient antimicrobials are often used in pediatric patients, few data exist regarding the frequency of adverse events (AEs) associated with these medications. METHODS: We performed a retrospective cohort study of all patients seen in the Infectious Diseases clinic at a tertiary referral children's hospital from August 1, 2009 to August 1, 2011. We included patients who received ≥14 days of oral or intravenous antibiotic, antiviral, or antifungal medications. Patients receiving only prophylactic medications or human immunodeficiency virus treatment were excluded. RESULTS: Three hundred thirty-five subjects met inclusion criteria, with a median age of 7.4 years at start of therapy. The cohort was predominantly male (60%), white (54%), and previously healthy (59%). A majority (88.4%) of subjects were treated for bacterial infections. β-Lactam agents were the most commonly used antimicrobial class (210 subjects; 62.7%), followed by clindamycin (86; 25.7%), rifampin (76; 22.7%), and vancomycin (62; 18.5%). Overall, 107 (31.9%) subjects experienced 151 distinct AEs. The most common individual AE noted was diarrhea (44; 29.1% of all AEs). Serious AEs developed in 42 (12.5%) subjects, including allergic reactions (15; 11.3% of all AEs), venous catheter-related complications (14; 13.0% of those with catheters), neutropenia (9; 3.0%), renal insufficiency (7; 2.5%), and hepatotoxicity (3; 1.1%). Rates of AEs were similar between those on oral and intravenous antimicrobials. CONCLUSIONS: In our study population, patients on prolonged oral or intravenous outpatient antimicrobials experienced AEs frequently. These findings support the need for close monitoring of pediatric patients on prolonged antimicrobial therapy and vigilance for unwanted effects of these medications.
BACKGROUND: Although long treatment courses of outpatient antimicrobials are often used in pediatric patients, few data exist regarding the frequency of adverse events (AEs) associated with these medications. METHODS: We performed a retrospective cohort study of all patients seen in the Infectious Diseases clinic at a tertiary referral children's hospital from August 1, 2009 to August 1, 2011. We included patients who received ≥14 days of oral or intravenous antibiotic, antiviral, or antifungal medications. Patients receiving only prophylactic medications or human immunodeficiency virus treatment were excluded. RESULTS: Three hundred thirty-five subjects met inclusion criteria, with a median age of 7.4 years at start of therapy. The cohort was predominantly male (60%), white (54%), and previously healthy (59%). A majority (88.4%) of subjects were treated for bacterial infections. β-Lactam agents were the most commonly used antimicrobial class (210 subjects; 62.7%), followed by clindamycin (86; 25.7%), rifampin (76; 22.7%), and vancomycin (62; 18.5%). Overall, 107 (31.9%) subjects experienced 151 distinct AEs. The most common individual AE noted was diarrhea (44; 29.1% of all AEs). Serious AEs developed in 42 (12.5%) subjects, including allergic reactions (15; 11.3% of all AEs), venous catheter-related complications (14; 13.0% of those with catheters), neutropenia (9; 3.0%), renal insufficiency (7; 2.5%), and hepatotoxicity (3; 1.1%). Rates of AEs were similar between those on oral and intravenous antimicrobials. CONCLUSIONS: In our study population, patients on prolonged oral or intravenous outpatient antimicrobials experienced AEs frequently. These findings support the need for close monitoring of pediatric patients on prolonged antimicrobial therapy and vigilance for unwanted effects of these medications.
Authors: Alan D Tice; Susan J Rehm; Joseph R Dalovisio; John S Bradley; Lawrence P Martinelli; Donald R Graham; R Brooks Gainer; Mark J Kunkel; Robert W Yancey; David N Williams Journal: Clin Infect Dis Date: 2004-05-26 Impact factor: 9.079
Authors: Jennifer Le; Michael San Agustin; Elvin A Hernandez; Tu T Tran; Felice C Adler-Shohet Journal: Clin Pediatr (Phila) Date: 2010-08-19 Impact factor: 1.168
Authors: Jean P Molleston; Robert J Fontana; M James Lopez; David E Kleiner; Jiezhun Gu; Naga Chalasani Journal: J Pediatr Gastroenterol Nutr Date: 2011-08 Impact factor: 2.839
Authors: Theoklis Zaoutis; A Russell Localio; Kateri Leckerman; Stephanie Saddlemire; David Bertoch; Ron Keren Journal: Pediatrics Date: 2009-02 Impact factor: 7.124
Authors: Nathan M Krah; Tyler Bardsley; Richard Nelson; Lawanda Esquibel; Mark Crosby; Carrie L Byington; Andrew T Pavia; Adam L Hersh Journal: Hosp Pediatr Date: 2019-04
Authors: Frank DiPaola; Jean P Molleston; Jiezhun Gu; Elizabeth T Cirulli; Naga Chalasani; Huiman Barnhart; David E Kleiner; Jay H Hoofnagle; Robert J Fontana Journal: J Pediatr Gastroenterol Nutr Date: 2019-08 Impact factor: 2.839
Authors: Jennifer L Goldman; Troy Richardson; Jason G Newland; Brian Lee; Jeffrey S Gerber; Matt Hall; Matthew Kronman; Adam L Hersh Journal: J Pediatric Infect Dis Soc Date: 2017-03-01 Impact factor: 3.164